360 related articles for article (PubMed ID: 19028999)
1. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.
Jacobs JF; Idema AJ; Bol KF; Nierkens S; Grauer OM; Wesseling P; Grotenhuis JA; Hoogerbrugge PM; de Vries IJ; Adema GJ
Neuro Oncol; 2009 Aug; 11(4):394-402. PubMed ID: 19028999
[TBL] [Abstract][Full Text] [Related]
2. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression.
Hatam LJ; Devoti JA; Rosenthal DW; Lam F; Abramson AL; Steinberg BM; Bonagura VR
Clin Cancer Res; 2012 Apr; 18(7):1925-35. PubMed ID: 22322668
[TBL] [Abstract][Full Text] [Related]
3. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.
Ghebeh H; Barhoush E; Tulbah A; Elkum N; Al-Tweigeri T; Dermime S
BMC Cancer; 2008 Feb; 8():57. PubMed ID: 18294387
[TBL] [Abstract][Full Text] [Related]
4. Low expressions of PD-L1 and CTLA-4 by induced CD4
Zhao L; Zhou X; Zhou X; Wang H; Gu L; Ke Y; Zhang M; Ji X; Yang X
Cytokine; 2020 Sep; 133():155119. PubMed ID: 32535334
[TBL] [Abstract][Full Text] [Related]
5. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
[TBL] [Abstract][Full Text] [Related]
6. Staphylococcus aureus convert neonatal conventional CD4(+) T cells into FOXP3(+) CD25(+) CD127(low) T cells via the PD-1/PD-L1 axis.
Rabe H; Nordström I; Andersson K; Lundell AC; Rudin A
Immunology; 2014 Mar; 141(3):467-81. PubMed ID: 24708420
[TBL] [Abstract][Full Text] [Related]
7. Programmed Death-1 antibody blocks therapeutic effects of T-regulatory cells in cockroach antigen-induced allergic asthma.
McGee HS; Yagita H; Shao Z; Agrawal DK
Am J Respir Cell Mol Biol; 2010 Oct; 43(4):432-42. PubMed ID: 19901343
[TBL] [Abstract][Full Text] [Related]
8. Human umbilical vein endothelial cells promote the inhibitory activation of CD4(+)CD25(+)Foxp3(+) regulatory T cells via PD-L1.
Chen WJ; Hu XF; Yan M; Zhang WY; Mao XB; Shu YW
Atherosclerosis; 2016 Jan; 244():108-12. PubMed ID: 26615520
[TBL] [Abstract][Full Text] [Related]
9. In-vitro effect of pembrolizumab on different T regulatory cell subsets.
Toor SM; Syed Khaja AS; Alkurd I; Elkord E
Clin Exp Immunol; 2018 Feb; 191(2):189-197. PubMed ID: 28963773
[TBL] [Abstract][Full Text] [Related]
10. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.
Karim R; Jordanova ES; Piersma SJ; Kenter GG; Chen L; Boer JM; Melief CJ; van der Burg SH
Clin Cancer Res; 2009 Oct; 15(20):6341-7. PubMed ID: 19825956
[TBL] [Abstract][Full Text] [Related]
11. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
12. Novel Effector Phenotype of Tim-3
Liu Z; McMichael EL; Shayan G; Li J; Chen K; Srivastava R; Kane LP; Lu B; Ferris RL
Clin Cancer Res; 2018 Sep; 24(18):4529-4538. PubMed ID: 29712685
[No Abstract] [Full Text] [Related]
13. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV.
Franceschini D; Paroli M; Francavilla V; Videtta M; Morrone S; Labbadia G; Cerino A; Mondelli MU; Barnaba V
J Clin Invest; 2009 Mar; 119(3):551-64. PubMed ID: 19229109
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.
Yang ZZ; Novak AJ; Stenson MJ; Witzig TE; Ansell SM
Blood; 2006 May; 107(9):3639-46. PubMed ID: 16403912
[TBL] [Abstract][Full Text] [Related]
15. Systemic and local immunosuppression in patients with high-grade meningiomas.
Li YD; Veliceasa D; Lamano JB; Lamano JB; Kaur G; Biyashev D; Horbinski CM; Kruser TJ; Bloch O
Cancer Immunol Immunother; 2019 Jun; 68(6):999-1009. PubMed ID: 31030234
[TBL] [Abstract][Full Text] [Related]
16. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
17. Reduced frequency and functional defects of CD4
Luo L; Zeng X; Huang Z; Luo S; Qin L; Li S
Reprod Biol Endocrinol; 2020 Jun; 18(1):62. PubMed ID: 32522204
[TBL] [Abstract][Full Text] [Related]
18. The possible regulatory effect of the PD-1/PD-L1 signaling pathway on Tregs in ovarian cancer.
Chen JX; Yi XJ; Gao SX; Sun JX
Gen Physiol Biophys; 2020 Jul; 39(4):319-330. PubMed ID: 32902402
[TBL] [Abstract][Full Text] [Related]
19. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
[TBL] [Abstract][Full Text] [Related]
20. The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro.
Yates J; Rovis F; Mitchell P; Afzali B; Tsang J; Garin M; Lechler RI; Lombardi G; Garden OA
Int Immunol; 2007 Jun; 19(6):785-99. PubMed ID: 17545278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
